Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabinoids for Immune Activation in HIV
NCT03550352Phase 2Terminated
- Sponsor
- McGill University Health Centre
- Start
- Aug 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nabiximols and cannabidiol in human immunodeficiency virus infection (HIV), sponsored by McGill University Health Centre. Started Aug 2021; status: terminated.
02
Drugs
nabiximolscannabidiol
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03550352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03550352.